We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.23B
AUM Growth
-$307M
Cap. Flow
+$10.8M
Cap. Flow %
0.88%
Top 10 Hldgs %
46.8%
Holding
78
New
13
Increased
11
Reduced
35
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.1M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$19.1M
3
TWST icon
Twist Bioscience
TWST
+$15.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$14.1M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$13.3M

Top Sells

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$40.7M
2
NKTR icon
Nektar Therapeutics
NKTR
+$33.1M
3
TSRO
TESARO, Inc.
TSRO
+$16.8M
4
OMER icon
Omeros
OMER
+$14M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
PUT
DELISTED
Sage Therapeutics
SAGE
$17.6M 1.43%
+184,000
New +$21.1M
SAGE
27
DELISTED
Sage Therapeutics
SAGE
$17.6M 1.43%
183,732
-6,268
-3% -$717K
SLDB icon
28
Solid Biosciences
SLDB
$859M
$17.5M 1.42%
43,532
-1,169
-3% -$550K
TCDA
29
DELISTED
Tricida, Inc. Common Stock
TCDA
$17.3M 1.4%
731,621
-2,967
-0.4% -$85.3K
TWST icon
30
Twist Bioscience
TWST
$7.16B
$16.3M 1.32%
+706,064
New +$15.6M
INCY icon
31
Incyte
INCY
$24.3B
$16M 1.3%
251,335
-8,665
-3% -$563K
NBIX icon
32
Neurocrine Biosciences
NBIX
$16.4B
$15.6M 1.27%
218,222
+43,222
+25% +$4.14M
INSP icon
33
Inspire Medical Systems
INSP
$1.73B
$12.3M 1%
290,239
-9,761
-3% -$415K
ARNA
34
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.7M 0.95%
300,000
-110,000
-27% -$4.32M
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.68B
$9.82M 0.8%
+90,000
New +$11.3M
AMRN
36
Amarin Corp
AMRN
$302M
$9.53M 0.77%
35,000
+10,000
+40% +$3.65M
ZGNX
37
CALL
DELISTED
Zogenix, Inc.
ZGNX
$9.12M 0.74%
250,000
– –
ARRY
38
DELISTED
Array Biopharma Inc
ARRY
$8.28M 0.67%
580,756
-19,244
-3% -$292K
NKTR icon
39
CALL
Nektar Therapeutics
NKTR
$2.47B
$8.22M 0.67%
16,667
-71,893
-81% -$43.4M
RARX
40
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$8.03M 0.65%
+441,000
New +$6.92M
ALLK
41
DELISTED
Allakos
ALLK
$7.84M 0.64%
+150,000
New +$7.52M
KURA icon
42
Kura Oncology
KURA
$817M
$7.72M 0.63%
+550,000
New +$7.29M
ORTX
43
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.9M 0.48%
+37,500
New +$5.59M
RUBY
44
DELISTED
Rubius Therapeutics, Inc
RUBY
$5.8M 0.47%
360,910
-3,649
-1% -$66.5K
EIDX
45
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$5.31M 0.43%
385,846
– –
CNST
46
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$5.1M 0.41%
1,271,687
– –
SRRK icon
47
Scholar Rock
SRRK
$5.74B
$4.83M 0.39%
210,078
– –
REPL icon
48
Replimune Group
REPL
$994M
$4.68M 0.38%
467,792
– –
CTMX icon
49
CytomX Therapeutics
CTMX
$729M
$4.48M 0.36%
+296,712
New +$4.4M
CFRX
50
DELISTED
ContraFect Corporation
CFRX
$4.45M 0.36%
3,632
-118
-3% -$187K
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Cormorant Asset Management held 78 positions worth $1.23B, down 20% from $1.54B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2018 filing shows 13 new, 11 increased, 35 reduced and 8 closed positions. Its largest new stake was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M. The largest sale was Autolus Therapeutics, an estimated $40.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2018 buy was Axonics, Inc. Common Stock: 1,285,828 shares worth $19.4M.
  • Cormorant Asset Management added most to argenx in Q4 2018, an estimated $23.1M increase.
  • Cormorant Asset Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $33.1M.
  • Cormorant Asset Management fully exited Autolus Therapeutics in Q4 2018, selling an estimated $40.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.23B portfolio in Q4 2018.
  • Cormorant Asset Management opened 13 new positions and closed 8 in Q4 2018.
  • Cormorant Asset Management's portfolio value fell 20% quarter-over-quarter to $1.23B.

Based on Cormorant Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.